Celltrion's Biosimilar User Fee Deadline Passes With Conspicuous Silence
This article was originally published in The Pink Sheet Daily
Executive Summary
Partnered with Hospira, Celltrion’s product referencing J&J’s Remicade (infliximab) would be second U.S. biosimilar, but appears to have been delayed.